
Chiara Gorrini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4904080/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Breast cancer immune microenvironment: from pre-clinical models to clinical therapies. Breast Cancer Research and Treatment, 2022, 191, 257-267.	1.1	10
2	The PTEN and ATM axis controls the G1/S cell cycle checkpoint and tumorigenesis in HER2-positive breast cancer. Cell Death and Differentiation, 2021, 28, 3036-3051.	5.0	7
3	Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis. EMBO Molecular Medicine, 2021, 13, e13929.	3.3	6
4	Immune Cell Associations with Cancer Risk. IScience, 2020, 23, 101296.	1.9	6
5	AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3604-3613.	3.3	96
6	Glutathione Metabolism: An Achilles' Heel of ARID1A-Deficient Tumors. Cancer Cell, 2019, 35, 161-163.	7.7	15
7	Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 4326-4335.	3.3	137
8	Glutathione Primes T Cell Metabolism for Inflammation. Immunity, 2017, 46, 675-689.	6.6	318
9	Fundamental Pathways in Breast Cancer 2: Maintenance of Genomic Stability. , 2017, , 13-17.		0
10	SBDS-Deficient Cells Have an Altered Homeostatic Equilibrium due to Translational Inefficiency Which Explains their Reduced Fitness and Provides a Logical Framework for Intervention. PLoS Genetics, 2017, 13, e1006552.	1.5	31
11	Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2. Cancer Cell, 2016, 30, 337-348.	7.7	166
12	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	1.1	34
13	Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression. Cancer Cell, 2015, 27, 314.	7.7	23
14	Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression. Cancer Cell, 2015, 27, 211-222.	7.7	748
15	Breaking up Is Hard to Do: PI3K Isoforms on the Rebound. Cancer Cell, 2015, 27, 5-7.	7.7	14
16	Estrogen controls the survival of BRCA1-deficient cells via a PI3K–NRF2-regulated pathway. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4472-4477.	3.3	100
17	Discovery of a p53 variant that controls metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11576-11577.	3.3	5
18	Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15. Genes and Development, 2013, 27, 1101-1114.	2.7	113

CHIARA GORRINI

#	Article	IF	CITATIONS
19	Modulation of oxidative stress as an anticancer strategy. Nature Reviews Drug Discovery, 2013, 12, 931-947.	21.5	2,735
20	BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. Journal of Experimental Medicine, 2013, 210, 1529-1544.	4.2	239
21	BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. Journal of Cell Biology, 2013, 202, 2022OIA57.	2.3	0
22	The E3 ubiquitin ligase Mule acts through the ATM–p53 axis to maintain B lymphocyte homeostasis. Journal of Experimental Medicine, 2012, 209, 173-186.	4.2	58
23	Acidic nuclear phosphoprotein 32kDa (ANP32)B-deficient mouse reveals a hierarchy of ANP32 importance in mammalian development. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 10243-10248.	3.3	38
24	Eukaryotic ribosomes host PKC activity. Biochemical and Biophysical Research Communications, 2008, 376, 65-69.	1.0	14
25	Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature, 2007, 448, 1063-1067.	13.7	296
26	Tip60 in DNA damage response and growth control: many tricks in one HAT. Trends in Cell Biology, 2006, 16, 433-442.	3.6	264
27	Analysis of Brostallicin Effect on Different Human Gastrointestinal Cancer Cell Lines. Letters in Drug Design and Discovery, 2006, 3, 524-527.	0.4	Ο
28	Fibronectin controls cap-dependent translation through Â1 integrin and eukaryotic initiation factors 4 and 2 coordinated pathways. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9200-9205.	3.3	36
29	E2F-Dependent Histone Acetylation and Recruitment of the Tip60 Acetyltransferase Complex to Chromatin in Late G 1. Molecular and Cellular Biology, 2004, 24, 4546-4556.	1.1	194
30	Release of eIF6 (p27BBP) from the 60S subunit allows 80S ribosome assembly. Nature, 2003, 426, 579-584.	13.7	375
31	Multiple effects of paclitaxel are modulated by a high c-myc amplification level. Experimental Cell Research, 2003, 290, 49-59.	1.2	21
32	Effect of apoptogenic stimuli on colon carcinoma cell lines with a different c-myc expression level. International Journal of Molecular Medicine, 2003, 11, 737.	1.8	7
33	Effect of apoptogenic stimuli on colon carcinoma cell lines with a different c-myc expression level. International Journal of Molecular Medicine, 2003, 11, 737-42.	1.8	15